ABIO ARCA biopharma Inc

Price (delayed)

$3.61

Market cap

$52.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2

Enterprise value

-$14.52M

Highlights
The company's quick ratio has surged by 66% QoQ
The company's equity rose by 42% QoQ
ARCA biopharma's net income has shrunk by 144% YoY and by 29% QoQ

Key stats

What are the main financial stats of ABIO
Market
Shares outstanding
14.41M
Market cap
$52.02M
Enterprise value
-$14.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.79
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$12.52M
EBITDA
-$12.44M
Free cash flow
-$11.29M
Per share
EPS
-$2
Free cash flow per share
-$0.91
Book value per share
$4.57
Revenue per share
$0
TBVPS
$5.6
Balance sheet
Total assets
$69.18M
Total liabilities
$3.27M
Debt
$394,000
Equity
$65.91M
Working capital
$65.85M
Liquidity
Debt to equity
0.01
Current ratio
23.86
Quick ratio
23.24
Net debt/EBITDA
5.35
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-27.3%
Return on equity
-28.9%
Return on invested capital
N/A
Return on capital employed
-18.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABIO stock price

How has the ARCA biopharma stock price performed over time
Intraday
-1.37%
1 week
-1.9%
1 month
7.44%
1 year
-48.13%
YTD
-9.98%
QTD
-1.1%

Financial performance

How have ARCA biopharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$12.53M
Net income
-$12.52M
Gross margin
N/A
Net margin
N/A
ARCA biopharma's net income has shrunk by 144% YoY and by 29% QoQ
ABIO's operating income has dropped by 133% year-on-year and by 28% since the previous quarter

Growth

What is ARCA biopharma's growth rate over time

Valuation

What is ARCA biopharma stock price valuation
P/E
N/A
P/B
0.79
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ARCA biopharma's EPS has increased by 42% YoY and by 3.4% from the previous quarter
The company's equity rose by 42% QoQ
ABIO's price to book (P/B) is 21% lower than its 5-year quarterly average of 1.0

Efficiency

How efficient is ARCA biopharma business performance
The return on equity has surged by 55% year-on-year and by 16% since the previous quarter
ARCA biopharma's return on assets has surged by 52% YoY and by 15% QoQ

Dividends

What is ABIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABIO.

Financial health

How did ARCA biopharma financials performed over time
ARCA biopharma's total liabilities has surged by 183% YoY but it has decreased by 16% QoQ
The company's current ratio has surged by 67% QoQ
The company's debt is 99% lower than its equity
The company's equity rose by 42% QoQ
The company's debt fell by 3.7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.